Novel COVID-19 antibody delivery approach advances to clinical trials

Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.

Related Keywords

United States ,Americans ,Pablo Tebas ,Laurent Humeau ,David Weiner ,Mark Esser ,Emily Henderson ,Indiana University ,Defense Health Agency ,Program Executive Office For Chemical ,Perelman School Of Medicine ,A Defense Advanced Research Projects Agency ,Astrazeneca ,Health Affairs ,Vaccine Immunotherapy Center ,Defense Advanced Research Projects Agency ,Office Of The ,University Of Pennsylvania ,Nuclear Defense ,Wistar Institute ,Joint Program Executive Office ,Charitable Trust Professor ,Cancer Research ,Infectious Diseases ,Perelman School ,Early Vaccines ,Immune Therapies ,Assistant Secretary ,Defense Health ,Antibodies ,Covid 19 ,Na ,Ntibody ,Dancer ,Clinical Trial ,Immunotherapy ,Laboratory ,Medicine ,Monoclonal Antibody ,Ucleic Acid ,Mh ,Pharmaceuticals ,Research ,Cars ,Ars Cov 2 ,Vaccine ,